obesity

Some Trump insiders are ready to take on the food industry. It remains to be seen whether their entree will result in any meaningful change in government oversight of “Big Food” — or in American health.

Will you still carry this added weight on New Year's Day 2026? For a quarter of us, that is probably going to prove true, according to a survey.

Although obesity remains one of our most pressing global health concerns, new research reveals an interesting twist.

Most people taking drugs like Ozempic and Wegovy have shed significant pounds. But obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust results with the medications.

After developing Type 2 diabetes and having a heart attack in his 40s, Clearwater resident Fabricio Zambrano switched to a plant-based lifestyle.

A report shows that obesity and overweight residents cost Florida $30.1 billion in 2022. Randall Croom, a Stetson management associate professor, says that’s taking a toll on our workforce and more.

Cheaper versions of Wegovy and Zepbound touted on social media could be fleeting. Copies are legal now because the brand-name drugs are in short supply. But the drugmakers are boosting production.

University of Sydney researchers found that obese individuals can benefit more from exercise between 6 p.m. and midnight. One theory is that the body is better primed later in the day to manage blood sugar.

New research shows that the number of 12- to 25-year-olds who used the GLP-1 medications climbed from about 8,700 a month in 2020 to 60,000 a month in 2023.

The makers of Ozempic and Mounjaro charge charge around $1,000 a month for the drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.